BMS Jan 26, 2023 BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Jan 10, 2023 JP Morgan Healthcare Conference, Day 1: Novartis, Bristol Myers Squibb, Mirati, Johnson & Johnson Jan 9, 2023 2seventy, Bristol Myers Squibb Improving Manufacturing Capacity for Abecma Dec 11, 2022 Bristol Myers Squibb, 2seventybio's Abecma Shows Benefit in High-Risk Multiple Myeloma Patients Premium Nov 28, 2022 NICE Recommends BMS's Opdivo Plus Chemo for HER2-Negative, PD-L1-Positive Gastric Cancer Nov 17, 2022 Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear Premium Nov 7, 2022 Automation Offers No Easy Answers to CAR T-Cell Supply Shortfalls Premium Nov 3, 2022 Kura Oncology Receives $25M Investment From Bristol Myers Squibb; Enters $125M Loan Agreement Oct 26, 2022 Bristol Myers Squibb Turns in Strong Q3 Opdualag Sales, Growth in CAR T Products Premium Oct 12, 2022 Early Data on GPRC5D-Directed CAR T-Cell Therapy Open Doors for New Myeloma Treatment Strategies Premium Oct 4, 2022 Autolus Therapeutics, BMS Partner to Develop Cell Therapies Equipped With Safety Switches Oct 4, 2022 Research Clarifies Immunotherapy, Targeted Treatment Order for BRAF-Mutant Melanoma Patients Premium Sep 29, 2022 New NIH-Funded Network Aims to Bring Precision to External Beam Radiation Treatment Premium Sep 19, 2022 EMA's CHMP Recommends Gilead's Yescarta for Second-Line Lymphoma Sep 16, 2022 BMS Combo Immunotherapy Opdualag Approved in Europe for Biomarker-Defined Melanoma Patients Sep 11, 2022 TIL Therapy Bests Yervoy in Head-to-Head Melanoma Trial; Will It Reach Patients Without Pharma? Premium Sep 10, 2022 BMS Combo Drug Opdualag Effective in Neoadjuvant NSCLC, But Maybe No Better Than Opdivo Alone Premium Sep 1, 2022 Multiple Myeloma Researchers Chip Away at Why Some Patients Relapse Quickly After CAR T-Cell Therapy Premium Aug 26, 2022 Melanoma Docs Resurrect PD-L1 Debate as CHMP, FDA Diverge on Opdualag Label Premium Aug 19, 2022 In Brief This Week: Genprex, Strata Oncology, Bristol Myers Squibb, Turning Point Therapeutics Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
